Insilico Medicine (“Insilico”), a generative artificial intelligence (AI)-driven clinical-stage drug discovery company, today announced the nomination of ISM8001, a novel molecule targeting FGFR2/3 for the treatment of tissue-agnostic solid tumors bringing the total number of PCCs nominated in 2023 to six.
Pfizer and BioNTech resolve mRNA patent lawsuit filed by Promosome
Promosome, Pfizer and BioNTech told a California federal judge that they have agreed to resolve Promosome’s lawsuit accusing the two companies of violating a patent